DENTSPLY SIRONA Inc.
Business
DENTSPLY SIRONA Inc. is a diversified manufacturer and marketer of professional dental products, technologies and healthcare consumables for urology and enterology. The Company offers dental technology and equipment, dental implants, clear aligners, restorative and preventive consumables, digital CAD/CAM systems, cloud-enabled services (DS Core), and continence care products. It operates through four reportable segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. Dentsply Sirona sells its products globally through third-party distributors, direct sales to dental professionals and laboratories, and digital platforms across approximately 150 countries.
Summary from filing dated 2025-02-27
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net sales | 3,680 | 3,793 | 3,965 | 3,922 | 4,231 | |
| Cost of products sold | 1,840 | 1,835 | 1,879 | 1,795 | 1,884 | |
| Gross profit | 1,840 | 1,958 | 2,086 | 2,127 | 2,347 | |
| Selling, general, and administrative expenses | 1,438 | 1,605 | 1,613 | 1,589 | 1,551 | |
| Research and development expenses | 150 | 165 | 184 | 174 | 171 | |
| Goodwill and intangible asset impairments | 650 | 1,014 | 307 | 1,287 | 0 | |
| Restructuring costs | 24 | 53 | 67 | 14 | 17 | |
| Operating loss | −422 | −879 | −85 | −937 | 608 | |
| Interest expense, net | 88 | 69 | 81 | 65 | — | |
| Other (income) expense, net | −24 | −12 | 9 | 53 | 2 | |
| Loss before income taxes | −486 | −936 | −175 | −1,055 | 545 | |
| Provision (benefit) for income taxes | 112 | −26 | −43 | −105 | 134 | |
| Net loss | −598 | −910 | −132 | −950 | 411 | |
| Less: Net loss attributable to noncontrolling interests | 0 | 0 | 0 | 0 | 0 | |
| Net loss attributable to Dentsply Sirona | −598 | −910 | −132 | −950 | 411 | |
| Basic (in dollars per share) | −3 | −4.48 | −0.62 | −4.41 | 1.88 | |
| Diluted (in dollars per share) | −3 | −4.48 | −0.62 | −4.41 | 1.87 | |
| Basic (in shares) | 199 | 203 | 212 | 216 | 218 | |
| Diluted (in shares) | 199 | 203 | 212 | 216 | 220 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2023 2023-06-30 | FY 2023 2023-03-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 326 | 272 | 334 | — | — | |
| Accounts and notes receivable-trade, net | 688 | 556 | 695 | — | — | |
| Inventories, net | 642 | 564 | 624 | — | — | |
| Prepaid expenses and other current assets | 367 | 354 | 320 | — | — | |
| Total Current Assets | 2,023 | 1,746 | 1,973 | — | — | |
| Property, plant and equipment, net | 861 | 766 | 800 | — | — | |
| Operating lease right-of-use assets, net | 139 | 136 | 178 | — | — | |
| Identifiable intangible assets, net | 974 | 1,207 | 1,705 | — | — | |
| Goodwill, net | 1,148 | 1,597 | 2,438 | 2,703 | 2,701 | |
| Other noncurrent assets | 284 | 301 | 276 | — | — | |
| Total Assets | 5,429 | 5,753 | 7,370 | — | — | |
| Accounts payable | 300 | 241 | 305 | — | — | |
| Accrued liabilities | 700 | 754 | 749 | — | — | |
| Income taxes payable | 30 | 45 | 49 | — | — | |
| Notes payable and current portion of long-term debt | 313 | 549 | 322 | — | — | |
| Total Current Liabilities | 1,343 | 1,589 | 1,425 | — | — | |
| Long-term debt | 2,015 | 1,586 | 1,796 | — | — | |
| Operating lease liabilities | 93 | 91 | 125 | — | — | |
| Deferred income taxes | 94 | 129 | 228 | — | — | |
| Other noncurrent liabilities | 544 | 415 | 502 | — | — | |
| Total Liabilities | 4,089 | 3,810 | 4,076 | — | — | |
| Commitments and contingencies (Note 21) | — | — | — | — | — | |
| Preferred stock, $1.00 par value; 0.25 million shares authorized; no shares issued | 0 | 0 | 0 | — | — | |
| Common stock, $0.01 par value; 400.0 million shares authorized at December 31, 2024 and 2023 264.5 million shares issued at December 31, 2024 and 2023 198.8 million and 207.2 million shares outstanding at December 31, 2024 and 2023, respectively | 3 | 3 | 3 | — | — | |
| Capital in excess of par value | 6,644 | 6,640 | 6,643 | — | — | |
| Accumulated deficit | −1,564 | −835 | 205 | — | — | |
| Accumulated other comprehensive loss | −639 | −730 | −636 | — | — | |
| Treasury stock, at cost, 64.9 million and 65.7 million shares at December 31, 2025 and 2024, respectively | −3,105 | −3,136 | −2,922 | — | — | |
| Total Dentsply Sirona Equity | 1,339 | 1,942 | 3,293 | — | — | |
| Noncontrolling interests | 1 | 1 | 1 | — | — | |
| Total Equity | 1,340 | 1,943 | 3,294 | — | — | |
| Total Liabilities and Equity | 5,429 | 5,753 | 7,370 | — | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 141 | 133 | 132 | 119 | 124 | |
| Amortization of intangible assets | 211 | 216 | 211 | 209 | 222 | |
| Goodwill impairment | 525 | 773 | 291 | 1,187 | 0 | |
| Intangible asset impairment | 125 | 241 | 16 | 100 | 0 | |
| Deferred income taxes | 30 | −136 | −130 | −228 | −25 | |
| Stock-based compensation expense | 33 | 39 | 46 | 59 | 48 | |
| Other non-cash (income) expense | −10 | −9 | 2 | 60 | 24 | |
| Loss (gain) on disposal of property, plant and equipment | 0 | 19 | −3 | 3 | — | |
| Accounts and notes receivable-trade, net | −91 | 104 | −58 | 85 | −117 | |
| Inventories, net | −17 | 17 | 6 | −141 | −64 | |
| Prepaid expenses and other current assets | −7 | 38 | −58 | −33 | −32 | |
| Other noncurrent assets | −7 | −5 | 4 | 1 | −10 | |
| Accounts payable | 11 | −30 | 14 | 30 | −49 | |
| Accrued liabilities | −74 | −39 | 17 | −6 | 117 | |
| Income taxes | −32 | 38 | −11 | −15 | 17 | |
| Other noncurrent liabilities | −5 | −28 | 30 | 1 | 12 | |
| Net cash provided by operating activities | 235 | 461 | 377 | 517 | 657 | |
| Cash received on sale of non-strategic businesses or product lines | 0 | 0 | 13 | 0 | 28 | |
| Capital expenditures | −131 | −180 | −149 | −149 | −142 | |
| Cash received on derivative contracts | 10 | 1 | 39 | 13 | 2 | |
| Cash paid on derivative contracts | −14 | −12 | 0 | 0 | — | |
| Other investing activities, net | 3 | −6 | 8 | −2 | 2 | |
| Net cash used in investing activities | −132 | −197 | −89 | −138 | −358 | |
| Proceeds from long-term borrowings | 553 | 1 | 0 | 6 | 16 | |
| Cash paid for deferred financing costs | −16 | 0 | 0 | — | — | |
| Repayments on long-term borrowings | −147 | −88 | −7 | −2 | −297 | |
| Proceeds from 364-day bridge loan | 435 | 0 | 0 | — | — | |
| Repayment of 364-day bridge loan | −435 | 0 | 0 | — | — | |
| (Repayments) proceeds on other short-term borrowings, net | −336 | 177 | 126 | — | — | |
| Cash paid for treasury stock | 0 | −250 | −300 | −150 | −200 | |
| Cash dividends paid | −128 | −126 | −116 | −104 | −92 | |
| Other financing activities, net | −6 | −16 | −10 | −15 | −36 | |
| Net cash used in financing activities | −80 | −302 | −307 | −329 | −379 | |
| Effect of exchange rate changes on cash and cash equivalents | 31 | −24 | −12 | −24 | −19 | |
| Net (decrease) increase in cash and cash equivalents | 54 | −62 | −31 | 26 | −99 | |
| Interest paid, net of amounts capitalized | 66 | 91 | 97 | 70 | 64 | |
| Income taxes paid, net of refunds | 71 | 74 | 177 | 122 | 148 | |
| Change in accounts payable related to capital expenditures | 37 | 8 | 6 | −6 | 19 | |
| Exchange of inventory for naming rights | 14 | 0 | 0 | — | — |